Merck enters tie-up with GSK worth up to €3.7 billionMerck KGaA and GlaxoSmithKline have agreed a tie-up worth up to €3.7 billion to the German group to jointly develop immunotherapy M7824 (bintrafusp alfa) for multiple cancers, FAZ (p21) and Welt (p13) reported on Wednesday.
Qiagen's tuberculosis diagnostic sales soared 21% in 2018German biotech Qiagen has reported soaring growth in sales for its tuberculosis diagnostic QuantiFERON-TB Gold, FAZ reported on Wednesday (p19).
MorphoSys and Janssen/Genmab settle patent lawsuitGerman biotech MorphoSys has settled its patent lawsuit with Janssen Pharmaceutica and Denmark's Genmab in the U.S. over Janssen/Genmab's Darzalex (daratumumab) for multiple myeloma (APMHE 61687), FAZ reported on Saturday (p22).
SecurPharm anti-counterfeit system to kick off SaturdayOn Saturday, SecurPharm anti-counterfeit system will be launched in German pharmacies (APMHE 61751), Die Welt reported on Wednesday (p13).
Merck investing $70 million in U.S. R&D centreMerck KGaA has announced a $70 million investment in its U.S. biologic drugs research centre in Billerica, Massachusets, FAZ reported on Thursday (p20).
Sanofi's orphan drugs and vaccines soar, Lantus slumpsSanofi said at its yearly results conference that sales of rare disease drugs at its Genzyme business soared 31% to €7.2 billion and vaccines by 2.4% to €5.1 billion in 2018, while sales of diabetes drug Lantus (insulin glargine) slumped by 19% to €3.65 billion after adjustment for currency effects, FAZ reports on Friday (p19 and 33).
Biosimilar competition for Allergan’s BotoxAllergan’s wrinkle prevention drug Botox is to face less expensive competition from Evolus’s biosimilar Jeuveau, which was granted U.S. approval by the Food and Drug Administration (FDA) on Monday (APMHE 61718), Die Welt (p9) and FAZ (p23) reported on Tuesday.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.